2003
Asymptomatic Infection with Borrelia burgdorferi
Steere A, Sikand V, Schoen R, Nowakowski J. Asymptomatic Infection with Borrelia burgdorferi. Clinical Infectious Diseases 2003, 37: 528-532. PMID: 12905137, DOI: 10.1086/376914.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBorrelia burgdorferiDouble-Blind MethodFemaleHumansLyme DiseaseLyme Disease VaccinesMaleMiddle AgedPrevalenceTreatment Outcome
2000
Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials